The results of the clinical study on the treatment of advanced lung squamous cancer of yew alcohol lipids were published

Lung cancer has the highest incidence and mortality rate of malignant tumors in the world, and as one of the common histological types of non-small cell lung cancer (NSCLC), the treatment of advanced lung squamous cancer still faces great challenges.
In recent years, the advent of new treatment strategies such as targeted therapy and immunotherapy has promoted landmark advances in the field of oncology, but how to choose the right immunotherapy drugs and design a combination of high-performance and low-toxic chemotherapy programs is still a major challenge in the clinical treatment of lung scale cancer.
Recently, a clinical study of advanced lung squamous cancer (LIPUSU), led by Shanghai Lung Hospital and involving Professor Zhou Caixuan and 35 central researchers, showed the direction for the clinical use of advanced lung squamous cancer.
on December 13, 2020, the LIPUSU research results will be held in Suzhou.
treatment of advanced lung squamous cancer should be safely advanced from November 2016 to December 2019, 540 patients with PS score 0-1 of IIIB-IV lung squamous cancer were randomly assigned by the central The yew alcohol lipids plus cisplatin group (LP group, n s268) and gisithamin siphol group (GP group, n s272), once every 3 weeks, were given 4-6 cycles.
results showed that the efficacy of the first-line treatment of advanced pulmonary squamous cancer was comparable to that of gissital-platinum in the near-term, and the total survival of the subjects of the first-line treatment of advanced pulmonary squamous cancer was longer than that of the GP group by 2.1 months (144) .6m vs12.5m), the two groups with a medium PFS of 5.2m and 5.5m (p.gt;0.05), respectively, showed no significant difference between the objective remission rate and the disease control rate in both groups (p>0.05).
assessment by an independent commission showed consistency in the best outcomes for both groups of patients.
In terms of safety, the adverse events (except hair loss) of all (≥30%) of the LP group were significantly lower than those in the GP group of the first-line treatment of advanced pulmonary squamous cancer in the first-line treatment of cisplatin (LP).
3-5 adverse events occurred in the GP group, with 3-5 levels of anemia (31.2% vs. 14.3%, P.lt;0.0001) and plateplate decline (14.1% vs.1.5%, P-lt;0.0001) significantly higher than the LP group.
addition, the proportion of yew alcohol lipids combined with cisplatin (LP) suspended or terminated due to adverse events or reactions was significantly lower than in the GP group.
, Professor Zhou Caisun of Shanghai Lung Hospital, said: "All treatment must be safe first, the purpose of drug treatment is to prolong the quality of life of patients, so that they live longer and with more dignity."
clinicians should prefer treatment with light toxic side effects and better efficacy, and patients can not only prolong their survival but also improve their quality of life after treatment.
" chemotherapy combined immune effect is better from the perspective of full management, the treatment of lung squamous cancer is still inseparable from chemotherapy.
because of low expression of PD-L1, very few patients with lung squamous cancer benefit from immunodrive monotherapy.
chemotherapy combined immunity can have a better effect.
yew alcohol lipids as a first-line drug to obtain the 2019/2020 CSCO Primary Lung Cancer Guidelines I recommendation, yew alcohol lipids combined cisplatin (LP) or carbapatin is the first-line option for the treatment of lung scale cancer.
Xiong Jianping, of Nanchang University's First Affiliated Hospital, who shares the progress of lung squamous cancer treatment research, said:
The doctor needs to find a balance between efficacy and side effects based on the individualization of the patient."
In the field of pulmonary squamous cancer, yew alcohol lipids as an ideal chemotherapy choice thanks to its unique mechanism of action, it can be through high permeability, long retention effect, targeting thickened in tumor tissue and lymph nodes, its effect on normal lymphocytes is small, low toxic side effects, and immunotherapy after the patient's benefits are greater.
The drug is more convenient to follow, in addition, a comparison of the results of recent classic lung squamous cancer research found that compared with albumin yew alcohol, gisithamin treatment plan, yew alcohol liposome combined platinum first-line treatment of advanced lung squamous cancer drug treatment is more convenient, each cycle (21 days) to give drugs once, the drug is more convenient, more dependent.
In fact, there is currently a relatively single treatment for advanced lung squamous cancer, so treatment based on the overall strategy is particularly important for patients with squamous cancer, especially when using the classic chemotherapy model, according to the characteristics of the patient to select the appropriate combination of drugs to enhance the overall safety and compliance, thereby maximizing the benefits to patients.
Shi Qin, of Fuzhou Lung Hospital in Fujian Province, who shared the cases, said: "Yew alcohol lipids are added to the team of optimal treatment programs for lung squamous cancer with more accurate and safer chemotherapy drugs.
LIPUSU study will provide a better basis for chemotherapy for patients with lung squamous cancer in China.
"Yew alcohol lipids combined with cisplatin (LP) first-line treatment of advanced lung squamous cancer research (LIPUSU) follow-up time, sampling range, rigorous design, data system.
study (LIPUSU) further strengthened the position of the first-line treatment of lung squamous cancer with yew alcohol lipids (LP), and filled the gaps in relevant fields both domestic and foreign.
in the age of precision medicine, chemotherapy remains the cornerstone of anti-tumor therapy.
combination of different treatment methods, including chemotherapy and targeted therapy, immunotherapy, radiotherapy and even surgery, as well as multidisciplinary collaboration, will greatly expand the treatment space for lung squamous cancer for the benefit of more patients.
。